

Chair of NERVTAG

Professor Peter Horby,
University of Oxford

Peter Horby is Director of the Epidemic diseases Research Group at the University of Oxford. He is a public health physician and clinical academic who trained in adult medicine, infectious diseases and public health in the UK and Australia. He was previously Director of the Oxford University Clinical Research Unit at the National Hospital for Tropical Diseases, Hanoi, Vietnam and has held positions with the UK Health Protection Agency and the World Health Organisation. He has worked extensively in resource constrained settings and has led research on a wide range of emerging and epidemic infections, including variant CJD, SARS, H5N1, H7N9, dengue, rabies, cholera, measles, rubella, *Streptococcus suis*, Hand Foot and Mouth Disease, and Ebola. Prof Horby advises the WHO on emerging infections.

NERVTAG Members

Professor Wendy Barclay
Imperial College London

Wendy Barclay took the Natural Science tripos at Cambridge, graduating in 1985. For her postgraduate study, Wendy infected human volunteers with rhinoviruses at the Common Cold Unit in Salisbury under the supervision of Dr David Tyrrell FRS, to understand the immune response to rhinovirus infection. In her first postdoctoral appointment Wendy joined Professor Jeff Almond at the University of Reading and learned the molecular virology skills, including the genetic engineering of small RNA viruses, that would form the technological basis of her research career. In 1992 she moved to the Mount Sinai Medical Center in New York and learned from Professor Peter Palese the techniques for recovery of recombinant influenza virus from cloned cDNA. Wendy returned to the University of Reading in 1995 and worked on influenza viruses there for 12 years. In May 2007 she moved with her group to take up a Chair in Influenza Virology at Imperial College London. She currently heads a team of around 10 scientists funded by the BBSRC, NC3Rs, and the EU. The lab studies many different aspects of the interaction between influenza viruses and their hosts. She is particularly interested in the mechanism by which viruses can cross from animal sources into humans to cause new pandemics. She is the current Chair of the Virus Division of the Society for General Microbiology. She sits on several advisory boards including that for The Roslin Institute as well as for the Science Media Centre. She has been a frequent contributor in the media on science issues particularly those concerning virus outbreaks.

Dr Matthew Donati
Public Health England

Matthew Donati is a clinical virologist working for Public Health England. He trained in medicine at University College London, obtained a PhD from the Royal Free Hospital London and undertook postgraduate training in virology at King's College Hospital in London. Dr Donati is the Public Health England influenza laboratory network clinical lead, contributing towards national respiratory virus guidance and surveillance activities. In addition, Dr Donati is a member of the UK advisory panel for healthcare workers infected with bloodborne viruses, a virology advisor to UK national external quality assurance service, and chair of the UK clinical virology network.

Professor John Edmunds
London School of Hygiene
and Tropical Medicine

Professor John Edmunds is the Dean of the Faculty of Epidemiology and Population Health at the London School of Hygiene and Tropical Medicine. His research interests centre on the use of mathematical models to guide infectious disease policy-making. He helped set up the flusurvey in the UK during the 2009 pandemic in response to gaps in the surveillance of

	<p>influenza. He has published over 250 peer-reviewed articles on topics ranging from HPV vaccination to the economics of measles eradication. He is a member of a number of national and international committees including WHO's Polio Research Committee and is on the Scientific Advisory Committee of the Coalition for Epidemic Preparedness Innovation (CEPI),. He is also a member of the UK's SPI-M (which provides modelling advice on pandemic influenza) and various subcommittees of the Joint Committee of Vaccines and Immunisation (JCVI – the UK's vaccine policy advisory body). Before taking up the Chair of Mathematical Modelling of Infectious Diseases at the LSHTM he was the Head of the Modelling and Economics Unit of the Health Protection Agency (now Public Health England). He still works closely with colleagues at PHE, particularly on immunisation-related issues.</p>
<p>Professor Neil Ferguson Medical Research Council</p>	<p>Neil Ferguson is director of the MRC Centre for Outbreak Analysis and Modelling and the NIHR Health Protection Research Unit for Modelling Methodology. He uses mathematical and statistical models to investigate the processes shaping infectious disease pathogenesis, evolution and transmission. His recent work has focused on the use of models as contingency planning tools for emerging human infections (notably Ebola and pandemic influenza), bioterrorist threats and livestock outbreaks, though he also undertakes research on the dynamics and control of vector-borne diseases (dengue, yellow fever and malaria) and pathogen evolution. He was educated at Oxford University where he also undertook postdoctoral research, then held a readership at the University of Nottingham before moving to Imperial College. Professor Ferguson is a Senior Investigator of the National Institute of Health Research, a Fellow of the UK Academy of Medical Sciences and received an OBE for his work on the 2001 UK foot and mouth disease epidemic. Prof Ferguson advises the UK and US governments, WHO and the EU on emerging infections and modelling.</p>
<p>Professor Andrew Hayward University College London</p>	<p>Andrew Hayward (BSc MBBS MSc DTM&H MD) is Professor of infectious disease epidemiology and Director of the UCL Institute of Epidemiology and Health Care. Andrew has extensive of epidemiological and public health research in infectious diseases with a particular focus on respiratory infections. Andrew has led research that underpins international influenza vaccination strategies for health care workers. He was chief investigator of the MRC/Wellcome Flu Watch studies which described the community epidemiology of seasonal and pandemic influenza. He is chief investigator of an NIHR pandemic preparedness grant which will monitor serological responses to the next pandemic. As Director of the Institute of Epidemiology and Health Care he leads around 300 population health and health care research scientists.</p>
<p>Dr Benjamin Killingley University College London Hospital Trust</p>	<p>Dr Ben Killingley is a consultant in Infectious Diseases and Acute Medicine at University College London Hospital Trust . He is a full time clinician working at the front door of hospital based services, and possess experience and knowledge of the workings of modern day acute medicine and how patients with infection are likely present to medical services and the care pathways that they may encounter. His research interest is the transmission of infection and he completed a PhD at the University of Nottingham in 2012 looking at how Influenza is transmitted amongst humans and was subsequently a lead investigator in a large CDC funded project involving human influenza challenge studies.</p>
<p>Professor Wei Shen Lim Nottingham University Hospitals NHS Trust</p>	<p>Wei Shen Lim is a Consultant Respiratory Physician working in a large teaching hospital – Nottingham University Hospitals NHS Trust, at the City Hospital Campus and Honorary Professor of Medicine, University of Nottingham. He has a specific interest in respiratory infections and was Chairman of the British Thoracic Society's Respiratory Infection Specialist Advisory</p>

	<p>Group, Chairman of the British Thoracic Society's Community Acquired Pneumonia Guidelines Committee, Guideline Development Group member for the NICE Pneumonia Guideline and Chairman of the joint British Thoracic Society, British Infection Society, Health Protection Agency and DoH Pandemic Influenza Clinical Management Guidelines Committee. He sat on the CMO's Pandemic Influenza Clinical and Operational (PICO) advisory group during the 2009-10 pandemic. He is Chief Investigator of a NIHR-funded pandemic influenza trial investigating Adjuvant Steroids in Adults with Pandemic Influenza (ASAP trial).</p>
<p>Dr Jim McMenamin Health Protection Scotland</p>	<p>Jim graduated from Glasgow University in 1987 (MBCbB) and trained in General Medicine (MRCP – Glasgow) and Infectious Diseases (DTM&H-London) before moving into Research in infection where he developed an interest in the Public Health aspects of Communicable Disease (MPH-Glasgow). He worked as a Consultant in Public Health Medicine/Communicable Disease in Greater Glasgow before moving to his current post in Health Protection Scotland. Jim is the strategic lead for the Respiratory Viral team within HPS and is responsible for seasonal and pandemic influenza. He currently co-chairs the Scottish Immunisation Programme Epidemiology and Surveillance group. Jim is very active in the area of assessment of seasonal influenza vaccine effectiveness through collaboration with EU partners in the IMOVE project. He has a keen interest in data linkage and works with a consortium of Scottish University & NHS Scotland colleagues on assessment of the impact of the seasonal influenza vaccination programme. Jim acted as an external advisor to the ECDC for the risk assessment of the 2011/12 and 2012/13 influenza season. He has secured in excess of £5 million of research and service development monies over the past seven years. He has over 90 publications across a range of infection topics.</p>
<p>Professor Peter Openshaw Imperial College London</p>	<p>Peter Openshaw is a respiratory physician, Professor of Experimental Medicine at the National Heart and Lung Institute, Imperial College London and the President of the British Society for Immunology. His research focuses on the immunology of the lung, viral lung disease, vaccination and viral immunopathogenesis. He has worked extensively on mouse models of respiratory syncytial virus disease (RSV) and led a consortium ('MOSAIC') studying immunopathogenesis in hospitalised patients with influenza. He conducts studies of human volunteers experimentally infected with RSV and influenza and leads an MRC-funded consortium HIC-vac, which promotes the use of infection challenge to accelerate vaccine development.</p> <p>He has served on many committees including the Department of Health's Scientific Advisory Group on Influenza (SAGE) and the Scientific Pandemic Influenza committee (SPI). He has co-authored over 230 scientific manuscripts (h-index 60). He is a member of ISARIC, the EU PREPARE and RESCEU consortia, Infection Theme Lead for the Imperial College Biomedical Research Centre, an NIHR Senior Clinical Investigator and a Consul of Imperial College (Clinical) and president of the International RSV Society.</p>
<p>Professor Calum Semple, University of Liverpool</p>	<p>Calum Semple is Professor of Child Health and Outbreak Medicine at the University of Liverpool. He was jointly appointed as Consultant in Paediatric Respiratory Medicine at Alder Hey in 2006. He was a co-investigator on FLU-CIN (2009-12) and MOSAIC (2010-2014), studies that characterised the clinical features and immunological response to Influenza A/H1N1pdm2009 infection.</p>

	<p>He is Chief Investigator for BESS (2018-), FLU-CATs (2013-), ISARIC-WHO Biological Sampling Protocol (2014-) and co-investigator on ARCHIE (2014-), all NIHR portfolio studies that study Severe Acute Respiratory Infection. He was Consortium Lead Investigator for the Ebola Convalescent Plasma study in Sierra Leone (Ebola_CP) and Co-Investigator on the sister study in Guinea (Ebola_Tx).</p> <p>He is an Honorary Senior Clinical Advisor to the CMO and Cabinet Office of HMG UK, and sat on the Pandemic Influenza Clinical Operational sub-group, Olympic Health group and Meningococcal Disease group. He is a member of the WHO Scientific Technical Advisory Committee on Ebola and is Senior Clinical Editor of Influenza and Other Respiratory Viruses.</p> <p>Calum provides a tertiary paediatric respiratory outpatient clinic and regional paediatric bronchoscopy service with colleagues at Alder Hey Children's Hospital in Liverpool.</p>
<p>Professor Robert Dingwall Dingwall Enterprises/Nottingham Trent University</p>	<p>Robert Dingwall is a consulting sociologist with Dingwall Enterprises Ltd and part-time professor at Nottingham Trent University. After studying at the Universities of Cambridge and Aberdeen, he worked at the Universities of Oxford and Nottingham. He has wide international experience in teaching and research, particularly in the interdisciplinary study of law, medicine, science and technology. Robert has chaired the Bioscience for Society Strategy Panel of the Biotechnology and Biological Sciences Research Council and previously served as a member of the Committee on Ethical Aspects of Pandemic Influenza and of the Civil Justice Council. He has also been a consultant to Roche on the ethical use of oseltamivir. He is a Fellow and Council member of the Academy of Social Sciences and an Honorary Member of the Faculty of Public Health.</p>
<p>Dr James Rubin Kings College London</p>	<p>James is an academic psychologist at King's College London, where he is a Reader in the Psychology of Emerging Health Risks. His main research interest is in understanding how people perceive health risks and what implications these perceptions have for how people behave and for their physical and mental well-being. He has published over 100 peer-reviewed academic papers on these and related topics.</p> <p>James's work covers two overlapping areas. The first assesses the importance of perceptions relating to suddenly occurring mass exposure to a potentially hazardous substance. Much of this work is conducted under the auspices of the NIHR Health Protection Research Unit in Emergency Preparedness and Response, which he is the assistant director for. The second area involves understanding how psychological and social factors can determine whether or not a person will develop symptoms following exposure to a potentially hazardous substance. James has previously published papers on why people attribute physical symptoms or seek health care following apparent exposure to mobile phone signals, wifi, police radio systems, common chemicals, wind turbines, swine flu, chemical terrorism and outbreaks of plague, among other things. As a result of his research, he has been invited to work with UK, EU and World Health Organisation bodies investigating the potential effects of newly identified health risks, and is an honorary non-medical consultant with the Emergency Response Department, Public Health England.</p>

Co-opted Members

<p>Dr Chloe Sellwood NHS England</p>	<p>Chloe Sellwood (BSc (Hons) PhD FRSPH DipHEP) is the National Lead Pandemic Influenza for NHS England, within the Emergency Preparedness, Resilience and Response (EPRR) Team. She leads NHS England pandemic influenza preparedness as a subject matter expert, and is coordinating national pandemic preparedness across the NHS, with a specific focus on London. Her experience in ranges from local to international levels and encompasses scientific, strategic and operational aspects. She spent over seven years at the HPA, including three years as the Senior Scientist and Coordinator of the Pandemic Influenza Office. In 2008 she joined NHS London (the then strategic health authority for London) as the Pandemic Influenza Resilience Manager, and in 2010 assumed the additional role of 2012 Health Resilience for the NHS across London for the Olympic and Paralympic Games. Since autumn 2014 she has additionally assumed the strategic leadership for NHS ebola preparedness in London. Since February 2017 she has been Deputy Head of the NHS England (London) EPRR team and was intrinsically involved in the response to the major incidents in London over summer 2017. She is the co-editor of, and a contributing author to, two textbooks on pandemic influenza, as well as many other articles and papers on influenza resilience. She has worked with WHO and ECDC on international consultations, as well as on secondment to the DH (England) Pandemic Influenza Preparedness Programme.</p>
<p>Dr Bob Winter NHS England</p>	<p>Bob Winter is a consultant in critical care at Nottingham University Hospitals NHS Trust and Medical Lead for the Mid-Trent Critical Care Network. In addition he is Chair of the National Network Medical Leads forum and was responsible for leading on the pandemic influenza surge response. He has been involved in the Intensive Care Society as a Council member (2002-2012), Honorary Secretary (2004-2007) and President (2009-2011, May-Dec 2012) and is currently an elected member of the Board of the Faculty of Intensive Care Medicine. Outside critical care he has an interest in trauma as a Major Trauma Consultant at Queens Medical Centre and Medical Lead for the East Midlands Major Trauma Network. Bob is a Member of the Advanced Trauma Life Support steering group (RCS England), Chair of the promulgation committee of ATLS Europe and Chair of the Pre-Hospital Trauma Life Support Steering Group (UK). Bob qualified in 1982 from Nottingham and trained in Nottingham, Burton on Trent, Truro, Bristol, Leicester, Mansfield and Back to Nottingham. Bob has an interest in motorsport and has been Chief Medical Officer for a wide range of national and international motorcycle events.</p>
<p>Professor Ian Brown Animal and Plant Health Agency</p>	<p>Professor Ian Brown is Head of Virology at the Animal and Plant Health Agency - Weybridge and Director of EU/OIE/FAO International Reference Laboratories for Avian Influenza, Newcastle Disease and Swine Influenza. Ian is the UK national expert on Avian and Swine Influenza and a designated OIE expert for the three diseases.</p> <p>Ian is a founder member of the OFFLU Laboratory Network and has taken the lead on a number of key international issues related to the work of this group both on the avian and swine subgroups. He provides a broad range of disease consultancy at both international and national level on all the aforementioned diseases, specialising in science evidence and laboratory application as directly relevant to disease control. His specific research interests include the epidemiology, pathogenicity, transmission and infection dynamics in relation to the control of influenza in animal hosts including zoonotic threat. Ian gained his PhD on 'Epizootiology of influenza in pigs in Great Britain with emphasis on characterisation of viruses isolated since 1986'. Ian holds a visiting Professorship position in Avian Virology at the University of Nottingham.</p>